The Technical Analyst
Atea Pharmaceuticals, [AVIR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Atea Pharmaceuticals, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.00% $3.76
America/New_York / 15 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 316.46 mill |
| EPS: | -1.630 |
| P/E: | -2.31 |
| Earnings Date: | May 05, 2024 |
| SharesOutstanding: | 84.16 mill |
| Avg Daily Volume: | 0.433 mill |
| RATING 2024-04-15 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.31 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.39x |
| Company: PE -2.31 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.696 (-54.90%) $-2.06 |
| Date: 2024-04-16 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.56 - 3.96 ( +/- 5.37%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-31 | Corcoran Andrea | Buy | 44 367 | Common Stock |
| 2024-02-01 | Corcoran Andrea | Sell | 15 843 | Common Stock |
| 2024-01-31 | Corcoran Andrea | Buy | 200 000 | Stock Option (Right to Buy) |
| 2024-01-31 | Corcoran Andrea | Sell | 44 367 | Restricted Stock Units |
| 2024-01-31 | Sommadossi Jean-pierre | Buy | 448 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 72.97 |
| Last 99 transactions |
| Buy: 22 764 762 | Sell: 12 804 280 |
Forecast:
16:00 - $3.76
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.76
Forecast 2: 16:00 - $3.76
Forecast 3: 16:00 - $3.76
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.76 (0.00% ) |
| Volume | 0.219 mill |
| Avg. Vol. | 0.433 mill |
| % of Avg. Vol | 50.48 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AVIR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $4.27 | N/A | Active |
|---|
AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Latest Press Releases
2024-03-27 07:00:00 - Press Release
Atea Pharmaceuticals Completes Patient Enrollment In Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir For Covid-19 In High-risk Patients
Enrollment reached over 2,200 high-risk patients in bemnifosbuvir monotherapy cohort results from sunrise-3 expected in 2h'24 boston, march 27, 2024 (globe newswire) -- atea pharmaceuticals, inc. (nasdaq: avir) (atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the company has completed enrollment of the global phase 3 sunrise-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, or placebo for the treatment of covid-19. over 2,200 patients were randomized into the supportive care monotherapy cohort and less than 80 patients were randomized into the combination cohort.
2024-02-28 16:05:00 - Press Release
Atea Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
Final results confirm 98% sustained virologic response rate at week 4 post-treatment (svr4) from lead-in cohort in phase 2 hcv study
2024-02-21 07:00:00 - Press Release
Atea Pharmaceuticals To Host Fourth Quarter And Full Year 2023 Financial Results Conference Call On February 28, 2024
Boston, feb. 21, 2024 (globe newswire) -- atea pharmaceuticals, inc. (nasdaq: avir) (“atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on wednesday, february 28, 2024, at 4:30 p.m. et to report financial results for the fourth quarter and full year ended december 31, 2023, and to provide a business update.
2024-01-08 16:05:00 - Press Release
Atea Pharmaceuticals Announces Positive Initial Data From Phase 2 Study For Hepatitis C Virus (hcv) And Significant Enrollment Milestone For Phase 3 Sunrise-3 Trial For Covid-19
A 98% sustained virologic response at week 4 (svr4) post-treatment observed in initial data from 52 patients in lead-in cohort in phase 2 hcv study
2024-01-03 07:00:00 - Press Release
Atea Pharmaceuticals To Present At The 42nd Annual J.p. Morgan Healthcare Conference
Boston, jan. 03, 2024 (globe newswire) -- atea pharmaceuticals, inc. (nasdaq: avir) (“atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that jean-pierre sommadossi, phd, chief executive officer and founder of atea, will present a business update at the 42nd annual j.p. morgan healthcare conference on wednesday, january 10, 2024 at 10:30 a.m. pt in san francisco, ca.
Latest News
2024-02-28 23:24:03 - Seeking Alpha
Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript
2024-02-21 07:00:00 - GlobeNewsWire
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, February 28, 2024, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2023, and to provide a business update.
2024-01-03 07:00:00 - GlobeNewsWire
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 10:30 a.m. PT in San Francisco, CA.
2023-11-08 18:51:05 - Seeking Alpha
Atea Pharmaceuticals, Inc. (AVIR) Q3 2023 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jonae Barnes - SVP, IR & Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman, CEO & President Janet Hammond - Chief Development Officer Arantxa Horga - Chief Medical Officer Andrea Corcoran - CFO, EVP, Legal & Secretary John Vavricka - Chief Commercial Officer Conference Call Participants Eric Joseph - JPMorgan Chase & Co. Maxwell Skor - Morgan Stanley Jonathan Miller - Evercore ISI Rosa Chen - Leerink Partners John Boyle - William Blair & Company Operator Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Third Quarter 2023 Financial Results and Business Update Conference Call.
2023-11-08 07:00:00 - GlobeNewsWire
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in and present a business update at the following investor conferences in November.
2023-11-01 07:00:00 - GlobeNewsWire
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, November 8, 2023, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2023, and to provide a business update.
2023-09-06 07:00:00 - GlobeNewsWire
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in a fireside chat and present a business update at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 10:10 a.m. ET.
2023-06-05 16:20:00 - GlobeNewsWire
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 2:00 p.m. ET.
2023-05-08 20:51:06 - Seeking Alpha
Atea Pharmaceuticals, Inc. (AVIR) Q1 2023 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q1 2023 Results Conference Call May 8, 2023 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder and Chief Executive Officer Andrea Corcoran - Financial Officer and Executive Vice President of Legal Janet Hammond - Chief Development Officer Conference Call Participants Maxwell Skor - Morgan Stanley John Miller - Evercore ISI Tim Lugo - William Blair Operator Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals' First Quarter 2023 Financial Results and Business Update Conference Call.
2023-05-01 16:05:00 - GlobeNewsWire
Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Monday, May 8, 2023, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2023, and to provide a business update.